GeneDx Diagnostic

by GeneDx  · Based in United States → — Advanced genetic testing for rare disease diagnosis
Laboratory Medicine Neurology Pediatrics
Website
Claim this tool
Is this the maker? Claim the company →

Variable, typically covered by insurance.
Regulatory Status Disclosed

Overview

GeneDx is a genomic diagnostics platform that provides AI-driven genetic testing and interpretation for rare and inherited disorders. Its primary goal is to enable physicians to achieve faster and more accurate diagnoses. The platform offers a comprehensive suite of genetic testing options, including whole exome sequencing, whole genome sequencing, and targeted panels, designed to deliver rapid and precise answers for complex conditions.

Leveraging GeneDx Infinity™, one of the world’s largest rare disease datasets, the company has performed over 2.5 million genetic tests, including nearly 1 million exomes and genomes sequenced, and boasts 8 million phenotypic data points. This extensive dataset, combined with advanced AI and clinical expertise, fuels deeper insights and contributes to a diagnostic yield 17% greater than standard testing. GeneDx serves a broad spectrum of clients including providers, patients and families, health systems, and biopharma companies, aiming to significantly reduce the average rare disease diagnosis time and mitigate misdiagnosis rates.

Key offerings include support for various medical specialties such as pediatric neurology, general pediatrics, and genetics, addressing indications like autism, epilepsy, and global developmental delay. The platform also features Epic Aura (EHR integration) and provides genetic counseling support, educational resources, and financial assistance programs to ensure accessibility and comprehensive care.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • AI-driven genetic testing and interpretation
  • Whole genome sequencing
  • Whole exome sequencing
  • Targeted testing options
  • Rapid and ultra-rapid testing
  • GeneDx Infinityu2122: Largest rare disease dataset (2.5M+ tests, 1M exomes/genomes, 8M phenotypic data points)
  • Industry-leading classification for actionable results
  • Genetic counseling support
  • Epic Aura (EHR integration)
  • Financial assistance programs

Use Cases

  • Diagnosing rare and inherited disorders
  • Accelerating drug discovery
  • Early detection and intervention in NICU
  • Identifying genetic links for autism
  • Providing clarity for adult and pediatric epilepsy
  • Personalized care for cerebral palsy

What Physicians Need to Know

Evidence Base
GeneDx leverages GeneDx Infinityu2122, one of the world's largest rare disease genomic datasets, comprising nearly 1 million exomes and genomes and over 7 million phenotypic data points. The company has contributed to over 1,100 peer-reviewed studies and identified more than 500 new gene-disease relationships. Their testing aligns with guidelines from the American College of Medical Genetics and Genomics (ACMG), American Academy of Pediatrics (AAP), National Society of Genetic Counselors (NSGC), and American Epilepsy Society (AES), which recommend exome and genome sequencing as first-line tests for various conditions, including developmental delay, intellectual disability, congenital anomalies, and unexplained epilepsy.
Clinical Validation Studies
GeneDx performs analytical validation studies for its Next Generation Sequencing (NGS), demonstrating a sensitivity of >99% for identifying single nucleotide variants (SNV). Their AI-powered decision support tool, Multiscore, has shown high sensitivity in 10,000 exomes and genomes, streamlining workflows and enhancing clinical insights. The company's research output includes numerous peer-reviewed studies and contributions to new gene-disease associations.
Differential Diagnosis Support
GeneDx's comprehensive exome and genome sequencing services are designed to support differential diagnosis by analyzing thousands of genes simultaneously. This approach increases the likelihood of identifying the underlying genetic cause of complex conditions, particularly for genetically heterogeneous presentations or broad/evolving differential diagnoses. The AI-powered Multiscore tool further assists by prioritizing genes based on alignment with a patient's clinical presentation, even in complex cases where symptoms may not fit textbook descriptions.
Clinical Workflow Integration
GeneDx has a significant integration with Epic Aura, a specialty diagnostics suite within Epic's electronic health records (EHR). This integration enables health systems to directly order GeneDx tests (including exome, whole genome, and rapid whole genome sequencing) and receive results seamlessly within their existing EHR workflow. This streamlines the diagnostic process, reduces manual data entry, minimizes errors, and improves overall efficiency for clinicians.
Decision Audit Trail
The genetic testing process with GeneDx involves a clear sequence: a doctor orders the test, samples are collected and sent for analysis, and results are shared and discussed with the doctor, often with guidance from genetic experts. The integration with EHR systems like Epic Aura means that test orders and the receipt of results are seamlessly logged within the patient's electronic health record, contributing to a traceable record of the diagnostic journey.
Physician Tip

1. **Prioritize Comprehensive Genomic Testing:** Consider exome or genome sequencing as a first-line test for patients with unexplained developmental delays, intellectual disabilities, congenital anomalies, or epilepsy, aligning with leading professional guidelines. n2. **Utilize Clinical Support:** Leverage GeneDx's dedicated team of board-certified genetic counselors and MDs for assistance with test selection, interpretation of complex results, and guidance on next steps for patient care. n3. **Understand VUS and Reanalysis:** Be aware that 'Variant of Uncertain Significance (VUS)' results may occur. GeneDx continuously monitors for new gene discoveries and reclassifications, and offers reanalysis at no additional charge upon request, which can lead to a definitive diagnosis over time. n4. **Leverage EHR Integration:** Maximize the benefits of the Epic Aura integration for efficient test ordering and seamless access to results directly within your existing EHR workflow, reducing administrative burden and accelerating time to diagnosis.

GeneDx offers robust integration with Epic Aura, a specialized diagnostics suite within Epic's EHR system. This integration allows healthcare providers to directly order GeneDx's advanced genetic tests, including exome sequencing (ES), whole genome sequencing (WGS), and rapid whole genome sequencing (rWGS), from within their native EHR environment. Results are then seamlessly transmitted back into the EHR, enhancing accessibility and visibility of genetic insights. This integration aims to eliminate manual data entry, reduce the risk of errors, and significantly streamline clinical workflows. GeneDx is committed to expanding its partnerships with other health systems and EHR platforms to further enhance access to genomic testing.

Details

Category Clinical Decision Support & Reference, Lab & Diagnostics
Pricing Variable, typically covered by insurance.
  • In-network for 79% of commercially insured patients; Medicaid coverage in 36 states; Financial Assistance Program available
DeploymentCloud-based
Compliance
BAA AvailableUnknown AI-estimated
HIPAA Compliant Yes AI-estimated
FDA Status Pending AI-estimated
Integrations
EHR Not specified
Specialties Laboratory Medicine, Neurology, Pediatrics

What the Web Says

GeneDx is generally viewed as a reputable and reliable diagnostic testing company, particularly for rare genetic disorders. Physicians appreciate their comprehensive testing panels and the quality of their genetic counseling services. While some users note the high cost of testing, the accuracy and depth of their reports are frequently highlighted as significant advantages.

Overall: Positive

Strengths

  • Comprehensive genetic testing panels for rare diseases
  • High accuracy and reliability of results
  • Strong genetic counseling support
  • Detailed and informative reports for clinicians
  • Experienced and knowledgeable staff
  • Focus on difficult-to-diagnose cases

Limitations

  • High cost of testing, potentially limiting accessibility
  • Turnaround times can sometimes be long for complex cases
  • Prior authorization processes can be cumbersome
  • Limited direct patient interaction outside of genetic counselors
  • Some reports may be overly technical for general practitioners
  • Customer service responsiveness can vary

Based on reviews from: Reddit (r/medicine, r/genetics), Physician forums and discussions, Healthcare IT reviews (general mentions), Genetic counseling professional forums, Academic papers citing GeneDx

Last updated: 2026-07-23

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate GeneDx Diagnostic

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

SEC.gov
GeneDx Reports Fourth Quarter and Full Year 2024 Financial Results and Issues Guidance for Full Year 2025
GeneDx reported strong financial results for Q4 and full year 2024, including significant growth in exome and genome test revenue, and provided optimistic guidance for 2025, expecting to reach profitability. The company also highlighted advancements in rapid whole genome sequencing and expanded access programs.
2025-02
HIT Consultant
GeneDx Launches on Epic Aura, Expanding Access to Genomic Testing
GeneDx announced its integration with Epic Aura, a specialty diagnostics suite within Epic's EHR, allowing healthcare providers to directly order genetic tests and receive results seamlessly, streamlining the diagnostic process. This collaboration aims to enhance access to genomic testing for patients.
2025-02
SEC.gov
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
GeneDx exceeded its financial expectations for Q3 2024, achieving positive adjusted net income ahead of schedule and reporting significant growth in exome and genome revenues. The company also highlighted its participation in genomic newborn screening studies and a publication in JAMA.
2024-10
SEC.gov
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
GeneDx reported strong second-quarter 2024 financial results, including increased revenues and improved adjusted gross margins, and updated its full-year 2024 guidance. The company also announced a collaboration with Epic Aura to expand access to rapid whole genome sequencing.
2024-07
Kalkine Media
GeneDx (NASDAQ:WGS) Stock Gains After AAP Endorses Russell 1000
GeneDx stock saw an upward trend after the American Academy of Pediatrics (AAP) released new clinical guidance recommending exome and genome sequencing as primary tests for children with developmental delays. This aligns with GeneDx's specialization in exome sequencing for rare and complex conditions.
2025-06
SEC.gov
GeneDx Reports Fourth Quarter and Full Year 2023 Financial Results and Issues Guidance for Full Year 2024
GeneDx reported strong financial performance for Q4 and full year 2023, with significant growth in exome and genome test revenue and expanded adjusted gross margins. The company also highlighted reaching over 1,000 peer-reviewed publications and expanding Medicaid coverage for genetic testing.
2024-02
MarketBeat
GeneDx Holdings (WGS) Stock Price, News & Analysis
GeneDx Holdings has had several recent news articles, including announcements about earnings reports and leadership changes. The company emphasizes its focus on rare disease genomics, prenatal diagnostics, and leveraging its large genomic dataset, GeneDx Infinity, for research and clinical insights.
2026-07
European Journal of Human Genetics
A head-to-head evaluation of the diagnostic efficacy and costs of trio versus singleton exome sequencing analysis
This peer-reviewed article from 2019 discusses the diagnostic efficacy and costs of trio versus singleton exome sequencing analysis, with GeneDx listed as a diagnostic lab contributing to the study. The research highlights the diagnostic rate of exome sequencing for severe genetic disorders.
2019-07

Videos

Product demos, reviews, and walkthroughs for GeneDx Diagnostic.

View all on YouTube

No FAQs available yet for this tool.

Related Tools

Cortex
Cortex
Clinical Decision Support & Reference
Cortex Workspace is a secure, HIPAA-compliant AI platform designed to streamline healthcare workflows and enhance decision-making for physicians.
Starts free, then $29/month for individual plan (save 10% annually). other plans: enthusiast ($99/month), business ($349/month), enterprise (contact sales).
SureMediks ProView
SureMediks (Rasimo Systems, LLC)
Clinical Decision Support & Reference
SureMediks is an AI-powered clinical decision support and metabolic health platform that automates care workflows for specialists, providing AI-generated patient summaries, automated chart review, and real-time biometric alerts.
SOAP Health
SOAP Health
Clinical Decision Support & Reference
SOAP Health is a Florida-based startup transforming patient intake with AI-powered diagnosis, offering a comprehensive solution that improves diagnosis accuracy and empowers patients and physicians.
Oxipit ChestLink
Oxipit (part of Sectra group)
Clinical Decision Support & Reference
Oxipit ChestLink is the world's first CE Class IIb-certified autonomous AI application for healthy chest X-ray reporting, capable of identifying normal studies with 99.9% sensitivity. It automates the reporting of normal chest X-rays, reducing radiologist workload and improving efficiency.
KATE AI
Mednition
Clinical Decision Support & Reference
KATE AI is a nurse-built clinical decision support tool for emergency departments that analyzes incoming patients in real-time to flag high-risk cases that standard acuity scoring might miss. It has supported over 5,000,000 patient visits, helping emergency teams deliver safer, faster, and more informed care.
Fee-based, not publicly disclosed.
MCG Health
MCG Health
Clinical Decision Support & Reference
MCG Health provides industry-leading evidence-based guidance and technologies to optimize health outcomes, drive operational efficiency, and achieve cost savings. Their solutions are utilized by thousands of hospitals, a majority of U.S. health plans, and various government health programs.
Contact for pricing

See all Clinical Decision Support & Reference tools →

Suggest an Edit → | Last Verified: 2026-04-22 | First Added: 2026-04-22
AI Tool Finder
AI-powered search. Results may not be comprehensive.